Comparison of the results with cost-effectiveness thresholds in PPP-USD in the base-year of the study.

Study	Country	Comparison	ICER (PPP-USD)	λ^2	50,000 USD	150,000 USD	500,000 USD	κ^1	3 GDP per capita	2 GDP per capita	1 GDP per capita
Bischof et al. 2022 Type I	United States USD/2021	Risdiplam OA	Dominance	Yes 150,000	Yes	Yes	Yes	Yes 24,283 - 40,112	Yes 207,861	Yes 138,574	Yes 69,287
Brazil, 2019 Early-onset	Brazil BRL/2019	Nusinersen BST	494,611	NA	No	No	Yes	No 3,210 - 10,122	No 46,074	No 30,716	No 15,358
Brazil, 2021 Late-onset	Brazil BRL/2021	Nusinersen BST	375,457	NA	No	No	Yes	No 3,210 - 10,122	No 48,168	No 32,112	No 16,056
Brazil, 2022a – 1 Early-onset	Brasil BRL/2022	Risdiplam Nusinersen	1,442,206	NA	No	No	No	No 3,210 - 10,122	No 48,168	No 32,112	No 16,056[5]
Brazil, 2022a – 2 Early-onset	Brasil BRL/2022	Risdiplam BST	2,306,120	NA	No	No	No	No 3,210 - 10,122	No 48,168	No 32,112	No 16,056[5]
Brazil, 2022a – 3 Early-onset	Brasil BRL/2022	Nusinersen BST	3,276,243	NA	No	No	No	No 3,210 - 10,122	No 48,168	No 32,112	No 16,056[5]
Brasil, 2022b – 1 Late-onset	Brasil BRL/2022	Risdiplam Nusinersen	23,994,735	NA	No	No	No	No 3,210 - 10,122	No 48,168	No 32,112	No 16,056[5]
Brazil, 2022b – 2 Late-onset	Brasil BRL/2022	Risdiplam BST	34,376,889	NA	No	No	No	No 3,210 - 10,122	No 48,168	No 32,112	No 16,056[5]
Brazil, 2022b – 3 Late-onset	Brasil BRL/2022	Nusinersen BST	43,618,020	NA	No	No	No	No 3,210 - 10,122	No 48,168	No 32,112	No 16,056[5]
CADTH, 2019 Type I	Canada CAD/2019	Nusinersen BST	551,425	No 41,425	No	No	No	No 21,051 - 26,564	No 147,897	No 98,598	No 49,299
CADTH, 2019 Type 2	Canada CAD/2019	Nusinersen BST	1,719,499	No 41,425	No	No	No	No 21,051 - 26,564	No 147,897	No 98,598	No 49,299

CADTH, 2019 Type 3	Canada CAD/2019	Nusinersen BST	2,366,046	No 41,425	No	No	No	No 21,051 - 26,564	No 147,897	No 98,598	No 49,299
CADTH, 2021 – 1 Early-onset	Canada CAD/2021	OA Nusinersen	Dominance	Yes 41,459	Yes	Yes	Yes	Yes 21,051 - 26,564	Yes 207,861	Yes 138,574	Yes 69,287
CADTH, 2021 – 2 Early-onset	Canada CAD/2021	OA BST	243,384 (sponsor) 277,023 (CADTH)	No 41,459	No	No	Yes	No 21,051 - 26,564	No 207,861	No 138,574	No 69,287
CADTH, 2021 – 3 Early-onset	Canada CAD/2021	Nusinersen BST	728,755	No 41,459	No	No	No	No 21,051 - 26,564	No 207,861	No 138,574	No 69,287
Dabbous et al. 2019 Type I	United States USD/2019	OA Nusinersen	Dominance	Yes 150,000	Yes	Yes	Yes	Yes 24,283 - 40,112	Yes 195,282	Yes 130,188	Yes 65,094
Dean et al. 2020 Type I	Japan JPY/2020	OA Nusinersen	Dominance	Yes 150,000	Yes	Yes	Yes	Yes 24,283 - 40,112	Yes 126,300	Yes 84,200	Yes 42,100
Dean et al. 2021 – 1 Type I	United States USD/2021	OA Nusinersen	Dominance	Yes 150,000	Yes	Yes	Yes	Yes 24,283 - 40,112	Yes 207,861	Yes 138,574	Yes 69,287
Dean et al. 2021 – 2 Type I	United States USD/2021	OA BST	161,648	No 150,000	No	No	Yes	No 24,283 - 40,112	Yes 207,861	No 138,574	No 69,287
Dean et al. 2021 – 3 Type I	United States USD/2021	Nusinersen BST	1,553,519	No 150,000	No	No	No	No 24,283 - 40,112	No 207,861	No 138,574	No 69,287
Hu et al. 2022 Type I	China CNY/2022	Risdiplam Nusinersen	Dominance	No 58,014[3]	Yes	Yes	Yes	Yes 2,013 - 7,957	Yes 58,014	Yes 38,676	Yes 19,338[5]
InCER 2019 – 1 Early-onset	United States USD/2017	Nusinersen BST	1,112,000	No 150,000	No	No	No	No 24,283 - 40,112	No 179,745	No 119,830	No 59,915
InCER 2019 – 2 Early-onset	United States USD/2017	OA BST	243,000	No 150,000	No	No	Yes	No 24,283 - 40,112	No 179,745	No 119,830	No 59,915

InCER 2019 – 3	United States	OA	139,000	Yes	No	No	Yes	No	Yes	No	No
Early-onset	USD/2017	Nusinersen		150,000				24,283 - 40,112	179,745	119,830	59,915
InCER 2019	United States	Nusinersen	8,156,000	No	No	No	No	No	No	No	No
Late-onset	USD/2017	BST		150,000				24,283 - 40,112	179,745	119,830	59,915
Malone et al. 2019	United States	OA	Dominance	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Type I	USD/2019	Nusinersen		150,000				24,283 - 40,112	195,285	130,190	65,095
Meyer et al. 2022 – 1	United States	Risdiplam	Dominance	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Type I	USD/2022	OA		150,000				24,283 - 40,112	207,861	138,574	69,287[5]
Meyer et al. 2022 – 2	United States	Risdiplam	Dominance	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Type I	USD/2022	Nusinersen		150,000				24,283 - 40,112	207,861	138,574	69,287[5]
Meyer et al. 2022 – 3	United States	OA	Dominance	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Type I	USD/2022	Nusinersen		150,000				24,283 - 40,112	207,861	138,574	69,287[5]
NCPE, 2017	Ireland	Nusinersen	602,971	No	No	No	No	No	No	No	No
Early-onset	EUR/2017	BST		54,152				21,071 - 26,634	233,247	155,498	77,749
NCPE, 2017	Ireland	Nusinersen	2,535,629	No	No	No	No	No	No	No	No
Late-onset	EUR/2017	BST		54,152				21,071 - 26,634	233,247	155,498	77,749
Thokala et al. 2020	United States	Nusinersen	1,112,000	No	No	No	No	No	No	No	No
Early-onset	USD/2017	BST		150,000				24,283 - 40,112	179,745	119,830	59,915
Wang et al. 2022 – 1	Australia	OA	1,255,011	NA	No	No	No	No	No	No	No
Type I	AUD/2022	BST						21,153 - 26,938	167,421	111,614	55,807[5]
Wang et al. 2022 – 2	Australia	Nusinersen	1,924,218	NA	No	No	No	No	No	No	No
Type I	AUD/2022	BST						21,153 - 26,938	167,421	111,614	55,807[5]
Wang et al. 2022 – 3	Australia	OA	859,325	NA	No	No	No	No	No	No	No
Type I	AUD/2022	Nusinersen						21,153 - 26,938	167,421	111,614	55,807[5]
Zuluaga-Sanchez et al.	Sweden	Nusinersen	640,967	No	No	No	No	No	No	No	No
2019a	SEK/2018	BST		79,203 –				21,148 - 26,917	160,563	107,042	53,521

Early-onset				138,040							
Zuluaga-Sanchez et al. 2019a Late-onset	Sweden SEK/2018	Nusinersen BST	450,966	No 79,203 – 138,040	No	No	Yes	No 21,148 - 26,917	No 160,563	No 107,042	No 53,522
Zuluaga-Sanchez et al. 2019b Early-onset	United States USD/2019	Nusinersen BST	>500,000	No 150,000	No	No	No	No 24,283 - 40,112	No 195,285	No 130,190	No 65,095
Zuluaga-Sanchez et al. 2019c Late-onset	United States USD/2019	Nusinersen BST	>500,000	No 150,000	No	No	No	No 24,283 - 40,112	No 195,285	No 130,190	No 65,095

[1]The values were taken from Woods et al. (2016) and has not been adjusted. Opportunity costs thresholds are not usually adjusted by inflation.2Results taken from implicit of explicit thresholds discussed by Santos et al. (2018).[3]Value taken from Ochalek et al. (2020).

Ochalek J, Wang H, Gu Y, Lomas J, Cutler H, Jin C. Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. Pharmacoeconomics. 2020 Dec;38(12):1319-1331. DOI: 10.1007/s40273-020-00954-y.

Santos AS, Guerra-Junior AA, Godman B, Morton A, Brandão CMR. Cost-Effectiveness Thresholds: methods for setting and examples from around the world. Expert Rev Pharmacoecon Outcomes Res. 2018;18(9):277–88.

Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Heal [Internet]. 2016;19(8):929–35. Available from: http://www.sciencedirect.com/science/article/pii/S1098301516000644.